USD 3.29
(-4.76%)
Year | Eps | Eps Growth |
---|---|---|
2024 | -0.45 USD | 35.71% |
2023 | -0.70 USD | 41.67% |
2022 | -1.20 USD | 58.33% |
2021 | -2.88 USD | 17.48% |
2020 | -3.49 USD | 30.06% |
2019 | -4.99 USD | 61.88% |
2018 | -13.09 USD | -82.57% |
2017 | -7.17 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.09 USD | 36.93% |
2024 FY | - USD | 35.71% |
2024 Q3 | -0.14 USD | -44.48% |
2024 Q4 | -0.10 USD | 28.57% |
2024 Q2 | -0.10 USD | -9.74% |
2023 FY | - USD | 41.67% |
2023 Q4 | -0.14 USD | -16.67% |
2023 Q3 | -0.12 USD | 20.0% |
2023 Q2 | -0.15 USD | 6.25% |
2023 Q1 | -0.16 USD | 15.79% |
2022 Q2 | -0.42 USD | -7.69% |
2022 Q1 | -0.39 USD | 4.88% |
2022 FY | - USD | 58.33% |
2022 Q4 | -0.19 USD | 24.0% |
2022 Q3 | -0.25 USD | 40.48% |
2021 Q3 | -0.30 USD | 26.83% |
2021 Q2 | -0.41 USD | -17.14% |
2021 FY | - USD | 17.48% |
2021 Q1 | -0.35 USD | 44.44% |
2021 Q4 | -0.41 USD | -36.67% |
2020 FY | - USD | 30.06% |
2020 Q1 | -1.22 USD | 4.69% |
2020 Q4 | -0.63 USD | 29.21% |
2020 Q3 | -0.89 USD | 27.64% |
2020 Q2 | -1.23 USD | -0.82% |
2019 Q2 | -0.98 USD | -38.03% |
2019 Q4 | -1.28 USD | -19.63% |
2019 FY | - USD | 61.88% |
2019 Q1 | -0.71 USD | 76.87% |
2019 Q3 | -1.07 USD | -9.18% |
2018 Q2 | -4.43 USD | -19.09% |
2018 FY | - USD | -82.57% |
2018 Q4 | -3.07 USD | 44.08% |
2018 Q3 | -5.49 USD | -23.93% |
2018 Q1 | -3.72 USD | -43.63% |
2017 Q3 | -2.29 USD | 0.0% |
2017 Q4 | -2.59 USD | -13.1% |
2017 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Arrowhead Pharmaceuticals, Inc. | -1.91 USD | 76.44% |
Codexis, Inc. | -1.12 USD | 59.821% |
Viridian Therapeutics, Inc. | -5.31 USD | 91.525% |
Organovo Holdings, Inc. | -1.60 USD | 71.875% |